Phase II Open Label Study of a Nebulised Nitric Oxide Generating Solution in Patients With Mycobacterium Abscessus Pulmonary Disease
Latest Information Update: 15 May 2024
At a glance
- Drugs Nitric oxide (Primary)
- Indications Nontuberculous mycobacterium infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms NOMAB
- 08 May 2024 Status changed from active, no longer recruiting to discontinued.
- 04 Jul 2023 Planned End Date changed from 26 Dec 2022 to 31 Oct 2024.
- 04 Jul 2023 Planned primary completion date changed from 1 Oct 2022 to 1 Oct 2024.